APA
Gullo G., J Eustace A., Canonici A., M Collins D., Kennedy M. J., Grogan L., Breathhnach O., McCaffrey J., Keane M., Martin M. J., Gupta R., Leonard G., O'Connor M., Calvert P. M., Donnellan P., Walshe J., McDermott E., Scott K., Hernando A., Parker I., W Murray D., C O'Farrell A., Maratha A., Dicker P., Rafferty M., Murphy V., O'Donovan N., M Gallagher W., Ky B., Tryfonopoulos D., Moulton B., T Byrne A. & Crown J. (2019). Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. : Therapeutic advances in medical oncology.
Chicago
Gullo Giuseppe, J Eustace Alex, Canonici Alexandra, M Collins Denis, Kennedy Michael J, Grogan Liam, Breathhnach Oscar, McCaffrey John, Keane Maccon, Martin Michael J, Gupta Rajnish, Leonard Gregory, O'Connor Miriam, Calvert Paula M, Donnellan Paul, Walshe Janice, McDermott Enda, Scott Kathleen, Hernando Andres, Parker Imelda, W Murray David, C O'Farrell Alice, Maratha Ashwini, Dicker Patrick, Rafferty Mairin, Murphy Verena, O'Donovan Norma, M Gallagher William, Ky Bonnie, Tryfonopoulos Dimitrios, Moulton Brian, T Byrne Annette and Crown John. 2019. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. : Therapeutic advances in medical oncology.
Harvard
Gullo G., J Eustace A., Canonici A., M Collins D., Kennedy M. J., Grogan L., Breathhnach O., McCaffrey J., Keane M., Martin M. J., Gupta R., Leonard G., O'Connor M., Calvert P. M., Donnellan P., Walshe J., McDermott E., Scott K., Hernando A., Parker I., W Murray D., C O'Farrell A., Maratha A., Dicker P., Rafferty M., Murphy V., O'Donovan N., M Gallagher W., Ky B., Tryfonopoulos D., Moulton B., T Byrne A. and Crown J. (2019). Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. : Therapeutic advances in medical oncology.
MLA
Gullo Giuseppe, J Eustace Alex, Canonici Alexandra, M Collins Denis, Kennedy Michael J, Grogan Liam, Breathhnach Oscar, McCaffrey John, Keane Maccon, Martin Michael J, Gupta Rajnish, Leonard Gregory, O'Connor Miriam, Calvert Paula M, Donnellan Paul, Walshe Janice, McDermott Enda, Scott Kathleen, Hernando Andres, Parker Imelda, W Murray David, C O'Farrell Alice, Maratha Ashwini, Dicker Patrick, Rafferty Mairin, Murphy Verena, O'Donovan Norma, M Gallagher William, Ky Bonnie, Tryfonopoulos Dimitrios, Moulton Brian, T Byrne Annette and Crown John. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. : Therapeutic advances in medical oncology. 2019.